NCT00090714Unknown2 期
To Find the Best Dose of pVGI.1(VEGF2) to Benefit Angina Patients When Given With an Experimental Injection Catheter
Corautus Genetics35 个研究点 分布在 1 个国家目标入组 404 人开始时间: 2004年8月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 404
- 试验地点
- 35
- 主要终点
- Exercise Tolerance
研究概览
简要总结
The purpose of this study is to determine the optimum effective dose of recombinant plasmid DNA [pVGI.1(VEGF2)] gene therapy administered using an experimental cardiac direct injection catheter (Stiletto™) system needed to benefit patients with severe Angina Pectoris.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Are willing and able to give informed consent
- •Have CCS class III or IV angina refractory to optimized medical therapy
- •Experience signs or symptoms of angina during the exercise tolerance test (ETT)
- •Have identified area(s) of reversible ischemic myocardium
- •Have procedurally acceptable targeted treatment zones
排除标准
- •Have exercise-limited non-cardiac chest discomfort
- •Unwilling or unable to undergo exercise testing
- •Able to exercise greater than 6 minutes on the treadmill
- •Are candidates for conventional revascularization procedures
- •Are or have been enrolled within 30 days, in another experimental study
- •Have had the most recent angiogram more than 6 Months prior to screening
- •Previously received an investigational angiogenic agent
- •Have another disease severe enough to limit exercise test or place patient at risk
- •Have uncontrolled: atrial fibrillation, atrial flutter, and/or significant arrhythmias
- •Have evidence of left ventricular aneurysm or ventricular thrombus
- •Are unwilling or unable to undergo cardiac catheterization or nuclear testing procedures
- •Have had a Q-wave MI, within 60 days
- •Have severe aortic valve stenosis or have a mechanical aortic or mitral valve
- •Have unstable angina or an acute non-Q-wave myocardial infarction within 14 days
- •Have had a documented stroke or transient ischemic attack within 60 days
- •Are pacemaker dependent
- •Have a recent history of active diabetic retinopathy or age-related wet macular degeneration
- •Have a history of cancer within the last 5 yrs. or have current evidence of a malignant neoplasm
- •Have a history of alcohol or drug abuse within 90 days
- •Are pregnant or lactating
- •Have reproductive potential and are unwilling to use condoms for contraception for 1 year after treatment - both male and female
- •Are unable to return to the clinic for the scheduled follow-up appointments
- •Are taking medications which may produce an undue risk
- •Have areas of LV wall less than 6mm thick
结局指标
主要结局
Exercise Tolerance
次要结局
未报告次要终点
研究者
研究点 (35)
Loading locations...
相似试验
已完成
1 期
PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced MalignancyNeoplasm RecurrenceNeoplasm MetastasisNCT01696565PhytoHealth Corporation32
招募中
1 期
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed OsteosarcomaRelapsed OsteosarcomaRelapsed NeuroblastomaRefractory OsteosarcomaRefractory NeuroblastomaNeuroblastomaNCT05400603Emory University24
撤回
1 期
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With CarcinomatosisCarcinomatosisAdvanced Solid TumorNCT06365918M.D. Anderson Cancer Center21
尚未招募
1 期
Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With MelanomaAdvanced MelanomaNCT03989895PrimeVax Immuno-Oncology Inc.10
终止
1 期
Study of Grifola Frondosa (Maitake), Azacitidine, and LenalidomideAdvanced CancersNCT01200004M.D. Anderson Cancer Center1